tradingkey.logo
tradingkey.logo
Search

argenx SE

ARGX
Add to Watchlist
947.520USD
-3.430-0.36%
Close 11-16 16:00(ET)
59.59BMarket Cap
39.17P/E TTM

About argenx SE Company

argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.

argenx SE Profile

Ticker SymbolARGX
Company nameargenx SE
IPO dateJul 10, 2014
CEOvan Hauwermeiren (Tim)
Number of employees1599
Security typeDepository Receipt
Fiscal year-endJul 10
AddressLaarderhoogtweg 25
CityAMSTERDAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryNetherlands
Postal code1101 EB
Phone31763030
Websitehttps://www.argenx.com/
Ticker SymbolARGX
IPO dateJul 10, 2014
CEOvan Hauwermeiren (Tim)

Company Executives of argenx SE

Name
Name/Position
Position
Shareholding
Change
Mr. Khurem Farooq
Mr. Khurem Farooq
Non-Executive Director
Non-Executive Director
--
--
Mr. Arjen Lemmen
Mr. Arjen Lemmen
Vice President - Corporate Development and Strategy
Vice President - Corporate Development and Strategy
--
--
Mr. James Michael (Jim) Daly
Mr. James Michael (Jim) Daly
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Anthony A. (Tony) Rosenberg
Mr. Anthony A. (Tony) Rosenberg
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Dr. Pamela M. (Pam) Klein
Dr. Pamela M. (Pam) Klein
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Peter K. M. Verhaeghe
Mr. Peter K. M. Verhaeghe
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Tim Van Hauwermeiren
Mr. Tim Van Hauwermeiren
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Peter Ulrichts
Mr. Peter Ulrichts
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Karen Massey
Ms. Karen Massey
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. Ana Cespedes
Dr. Ana Cespedes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Khurem Farooq
Mr. Khurem Farooq
Non-Executive Director
Non-Executive Director
--
--
Mr. Arjen Lemmen
Mr. Arjen Lemmen
Vice President - Corporate Development and Strategy
Vice President - Corporate Development and Strategy
--
--
Mr. James Michael (Jim) Daly
Mr. James Michael (Jim) Daly
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Anthony A. (Tony) Rosenberg
Mr. Anthony A. (Tony) Rosenberg
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Dr. Pamela M. (Pam) Klein
Dr. Pamela M. (Pam) Klein
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Peter K. M. Verhaeghe
Mr. Peter K. M. Verhaeghe
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--

FAQs

Who are the top five shareholders of argenx SE?

The top five shareholders of argenx SE are: Mr. Tim Van Hauwermeiren

How many institutions hold shares of argenx SE (ARGX)?

As of 2026Q1, 942 institutions hold shares of argenx SE, with a combined market value of approximately 31.47M, accounting for 50.86% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -2793210.00.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.